Matinas BioPharma (NYSEAMERICAN:MTNB) Posts Quarterly Earnings Results, Hits Expectations

Matinas BioPharma (NYSEAMERICAN:MTNBGet Rating) released its earnings results on Thursday. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03), MarketWatch Earnings reports.

Shares of MTNB opened at $0.67 on Friday. Matinas BioPharma has a 1-year low of $0.49 and a 1-year high of $1.61.

A number of institutional investors and hedge funds have recently made changes to their positions in MTNB. Citadel Advisors LLC purchased a new position in Matinas BioPharma during the 3rd quarter valued at about $241,000. LPL Financial LLC increased its position in Matinas BioPharma by 78.1% during the 3rd quarter. LPL Financial LLC now owns 277,684 shares of the company’s stock valued at $361,000 after purchasing an additional 121,726 shares during the period. Jane Street Group LLC increased its position in Matinas BioPharma by 567.4% during the 3rd quarter. Jane Street Group LLC now owns 162,141 shares of the company’s stock valued at $211,000 after purchasing an additional 137,847 shares during the period. Bank of America Corp DE increased its position in Matinas BioPharma by 7,927.9% during the 4th quarter. Bank of America Corp DE now owns 146,348 shares of the company’s stock valued at $148,000 after purchasing an additional 144,525 shares during the period. Finally, Geode Capital Management LLC increased its position in Matinas BioPharma by 13.8% during the 4th quarter. Geode Capital Management LLC now owns 1,586,863 shares of the company’s stock valued at $1,602,000 after purchasing an additional 192,119 shares during the period. Institutional investors own 12.40% of the company’s stock.

Several research firms have recently issued reports on MTNB. Zacks Investment Research lowered shares of Matinas BioPharma from a “buy” rating to a “hold” rating in a report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of Matinas BioPharma in a report on Wednesday, March 9th.

About Matinas BioPharma (Get Rating)

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.

See Also

Earnings History for Matinas BioPharma (NYSEAMERICAN:MTNB)

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.